Business Development

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Merck KGaA’s head of global research and development, Luciano Rossetti, sat down with In Vivo to discuss the track the German company is taking toward becoming a major player in global immuno-oncology. Tap in to his insights and opinions in this essential interview.

March 11, 2019

How Roche Won The Bidding Battle For Spark

Go behind the scenes with Scrip, as expert analysts examine the machinations of Roche’s acquisition of Spark Therapeutics, Inc. Find out in this informative article how Roche secured the deal in the face of strong competition from three other rival companies.

March 8, 2019

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Gene therapy continues to be a hot area of investment, even as the inevitable challenges concerning manufacturing and reimbursement remain a concern. Take a look at the major deals in this area with expert reporting from Scrip.

March 1, 2019

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

Expect more industry consolidation, counsels Morningstar’s Healthcare Observer report. Among the potential deals: BioMarin is a logical acquisition target. But for whom? Find out what Morningstar’s Damien Conover predicts. Discover which companies could be targets for Pfizer, and learn what Conover thinks of Pfizer CEO Albert Bourla’s insistence that it plans to grow organically.

February 18, 2019

Modernizing FDA’s Supplement Industry Regulation Mapped Out In Five-Point Plan

Before stepping down as FDA commissioner, Scott Gottlieb announced “one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years.” Through warning letters and advisory letters, the agency is already signaling a move toward more aggressive enforcement. Find out about the agency’s five-point plan and how FDA plans to balance innovation with regulation.

February 11, 2019

What Does 2019 Hold For Biopharma?

What will be the biggest trends in biopharma during 2019? In Vivo brings you the predictions of various industry experts, who weigh in on their predictions for what 2019 may hold for R&D, market access, digital and AI, and the organizations and people who play a key role in the industry.

January 23, 2019

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

The second day of the 2019 JP Morgan Healthcare Conference has concluded, and Pink Sheet was there to bring you all of the breaking news, major announcements, and insights from the largest investment healthcare symposium in the world.

January 9, 2019

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

Major deal news, exciting new scientific developments, and an atmosphere of bold enthusiasm masked concerns over US drug pricing and political worries at the 2019 J.P. Morgan Healthcare Conference in San Francisco. Scrip was there to report on what was discussed – and what wasn’t – at the largest pharma-industry business meeting of the year.

January 9, 2019

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb

Scrip reports from Day 2 of the 2019 J.P. Morgan Healthcare Conference, bringing you the highlights to come out of the San Francisco meeting. Read the most important news from Day 2, including the latest from Biogen, updates on GSK’s oncology efforts, deal developments for bluebird and Lilly, and more.

January 9, 2019

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

As the pharmaceuticals industry gets its issues with data integrity under control, a new challenge has arisen, according to US FDA comments at a recent meeting of the International Society for Pharmaceutical Engineering. Find out how these out-of-specification investigation (OOS) issues are playing out, with expert reporting from Pink Sheet.

January 6, 2019

Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

Bayer AG is seeking to turn around its troubled Consumer Health division through implementing key portfolio changes and embracing growth-focused innovation, according to Heiko Schipper, President of Consumer Health. Find out what’s in store for Bayer AG’s Consumer Health group, straight from its top leadership.

December 17, 2018

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

In the wake of new CEO Vas Narasimhan, and like several of its peers in the industry, Novartis AG recently announced it was paring back their pipeline, from 430 products to 340. Find out which products got the axe and what the focus of the company will be in the months and years to come in this illuminating article from Scrip.

December 13, 2018

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

The 2018 Nobel Prize for Chemistry was recently jointly awarded to George Winter and two other scientists for their pioneering work in the directed evolution of antibodies, research which led to the development of Humira, the world’s most successful drug.

December 9, 2018

Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown

The BCMA CAR-T therapies gap between industry leaders Celgene and bluebird bio and their competition in the space is closing, according to data released at the December 2018 American Society of Hematology (ASH) meeting in San Diego.

December 4, 2018